GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US clinical stage caner drug developer Theriva Biologics revealed that the US Food and Drug Administration (FDA) has granted Rare Pediatric Drug designation (RPDD) for VCN-01 for the treatment of retinoblastoma. 1 August 2024
Eisai and Biogen have announced that Israel has approved their Alzheimer's treatment, Leqembi (lecanemab), adding to nods in the USA, Japan, China, South Korea, and Hong Kong. 12 July 2024
Contract research and development organization (CDMO) Emergent BioSolutions has announced that Johnson & Johnson will pay $50 million to resolve claims linked to a terminated manufacturing deal for the latter’s COVID-19 vaccine. 11 July 2024
Japan’s Eisai and US biotech Biogen have announced that the Department of Health in Hong Kong has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) for treatment of Alzheimer’s disease (AD). 11 July 2024
PolTREG, a Polish biotech developing cell therapies for autoimmune diseases, has announced that its polyclonal Treg cell therapy PTG-007 demonstrated significant insulin secretion restoration in early-onset type-1 diabetes (T1D) patients, as well as a longer period of disease remission compared to a control group receiving standard-of-care. 24 June 2024
Indian drugmaker Cipla announced that its wholly-owned subsidiary in the UK, Cipla (EU) Limited, will invest an additional 3 million euros ($3.2 million) in Ethris GmbH, a German firm delivering mRNAs directly to the respiratory system. 19 June 2024
Dutch autoimmune diseases specialist Argenx announced that results from the Phase II ALPHA study of efgartigimod in post-COVID-19-mediated postural orthostatic tachycardia syndrome (PC-POTS) show that treated patients had no clinically meaningful improvement compared to placebo on the total Malmö POTS symptom (MaPS) score and COMPASS31. 17 June 2024
The US Food and Drug Administration (FDA) has accepted Eisai’s supplemental Biologics License Application (sBLA) for monthly Leqembi (lecanemab-irmb) intravenous (IV) maintenance dosing. 10 June 2024
The European Medicines Agency (EMA) has approved a Type II variation to the Summary of Product Characteristics (SmPC) for its approved Chimeric Antigen Receptor (CAR) T-cell therapies, Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel) from Gilead Sciences’ Kite subsidiary. 6 June 2024
A positive Phase III result in ulcerative colitis will support the ongoing commercial success of AbbVie’s JAK blocker Skyrizi (risankizumab). 24 March 2023
US biotech Biogen is focusing on the positives after a US Food and Drug Administration (FDA) advisory committee (AdCom) meeting on tofersen, an investigational product for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). 23 March 2023
Clay Siegall is leaping back into the biotech world as chief executive and president of Morphimmune, a pre-clinical biotechnology company focused on developing targeted oncology therapeutics based in Seattle, USA. 23 March 2023
UK immune-oncology company Macomics has entered into a worldwide drug discovery collaboration with Japan’s Ono Pharmaceutical to develop new antibody drugs against a novel macrophage target of interest in cancer. 23 March 2023
Sanofi shares were more than 5% higher by lunchtime on Thursday after the French company’s prized asset - its Regeneron (Nasdaq: REGN)-partnered biologic Dupixent (dupilumab) - delivered more stunning trial results. 23 March 2023
On 22 March 2023, the provisional registration of Tecentriq (atezolizumab) for the treatment of metastatic triple-negative breast cancer (mTNBC) will lapse, meaning that Tecentriq will no longer be approved for this use, Australian medicines regulator the Therapeutics Goods Administration (TGA) announced today. 22 March 2023
Cambridge, USA-based discoverer of precision medicines for cancer and other diseases Flare Therapeutics today announced an oversubscribed $123 million Series B financing. 22 March 2023
Beam Therapeutics, a US biotech developing precision genetic medicines through base editing, has named Gopi Shanker its chief scientific officer (CSO). 22 March 2023
Primary overall survival (OS) analysis results of the Phase III ZUMA-7 study have been released by US biotech major Gilead Sciences’ subsidiary Kite. 22 March 2023
Positive data for a new kind of cancer med, targeting the CLDN18.2 biomarker, will be presented at the March Plenary Series of the American Society of Clinical Oncology (ASCO). 22 March 2023
Just a couple of years ago, shares in US biotech Sangamo Therapeutics were worth more than $13, but the latest dose of bad news on the company has led them to drop below $2. 21 March 2023
US biotech major Gilead Sciences has exercised its option to exclusively license Nurix Therapeutics’ investigational targeted protein degrader molecule NX 0479, with the news sending the latter’s share price up 6.5% to $9.60 by late afternoon on Monday. 21 March 2023